Combining Cytotoxic Chemotherapy With Cyclooxygenase-2 Inhibition
- 15 July 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (14) , 2631-2632
- https://doi.org/10.1200/jco.2003.02.044
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Lung Cancer Prevention*Chest, 2003
- IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9–12, 2001Lung Cancer, 2002
- Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lungLung Cancer, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2Journal of Biological Chemistry, 2000
- Inhibitors of lipoxygenase: a new class of cancer chemopreventive agentsCarcinogenesis: Integrative Cancer Research, 1998
- Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J miceCarcinogenesis: Integrative Cancer Research, 1997
- Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective StudyEpidemiology, 1994